Efficacy News and Research

RSS

Intellikine commences INK1117 Phase I dose escalation study in cancer

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

12 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years "to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue," the Associated Press/Washington Post reports.

12 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Three randomized controlled trials published Online First today in Archives of Internal Medicine examine the effectiveness of behavioral and educational interventions for patients with poorly controlled diabetes.

11 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.

10 Oct 2011

AIT Laboratories introduces new suite of services for prescription compliance monitoring

Chronic pain affects an estimated 116 million adults in the U.S.—more than the number affected by heart disease, diabetes, and cancer combined, according to a recent report by the Institute of Medicine.

10 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011

Researchers focus on gelatinase inhibitor compounds to treat neurological diseases

Results of a study by a group of University of Notre Dame researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases.

10 Oct 2011

New $13.75M data-mining project to better understand factors behind mental disorders

Chicago will be home to a new $13.75 million project that will apply data mining methods to better understand the genetic and environmental factors behind neuropsychiatric disorders.

7 Oct 2011

Virginia Bioinformatics Institute releases upgraded ENISI software

Researchers with the Virginia Bioinformatics Institute at Virginia Tech have released an upgrade to the institute's ENteric Immunity SImulator (ENISI) software, which models immune responses to beneficial and harmful bacteria that enter the gastrointestinal tract of mice, pigs, and humans.

7 Oct 2011

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus.

4 Oct 2011

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

The first patient has now been included in Karo Bio's phase III trial with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.

4 Oct 2011

New review explores how nanotechnology may develop safer breast implants

A new review published in WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology may be used to develop safer breast implants as an alternative to silicone rubber, minimizing health complications.

4 Oct 2011

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.

4 Oct 2011